SGLT2 Inhibition Reduces Vascular Dysfunction in Aged Mice
We report that Empa-treated mice exhibited improved mesenteric endothelial function compared with control, in parallel with reduced mesenteric artery and aortic stiffness. Our findings demonstrate that Empa improves endothelial function and reduces arterial stiffness in a preclinical model of aging, making SGLT2 inhibition a potential therapeutic alternative to reduce the progression of cardiovascular disease in older individuals.
Link: https://doi.org/10.1007/s11357-022-00563-x
Source: Fight Aging! - Category: Research Authors: Reason Tags: Daily News Source Type: blogs
More News: Cardiology | Cardiovascular | Clinical Trials | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Heart Attack | Jardiance | Research | SGLT2 Inhibitors | Stroke | Weight Loss